ライフサイエンスコーパス: dysautonomia

1 and sympathetic nervous system dysfunction (dysautonomia).

2 ptors cause acute postganglionic cholinergic dysautonomia.

3 ysfunction, urinary tract malformations, and dysautonomia.

4 cal features such as vibratory urticaria and dysautonomia.

5 ized by parkinsonism, cerebellar ataxia, and dysautonomia.

6 structural plasticity and the development of dysautonomia.

7 m a therapeutic opportunity to treat cardiac dysautonomia.

8 , breathlessness, neurocognitive effects and dysautonomia.

9 between subjective and objective measures of dysautonomia.

10 uanylate cyclase coupling to cGMP in cardiac dysautonomia.

11 r Ca(2+) impairment underpinning sympathetic dysautonomia.

12 laints, connective tissue abnormalities, and dysautonomia.

13 mpathetic dysfunction similar to humans with dysautonomia.

14 esponsible for the milder course in familial dysautonomia.

15 nt disorders, reduction in consciousness and dysautonomia.

16 ion abnormalities and profound physiological dysautonomia.

17 and this syndrome and others with associated dysautonomia.

18 (AAN) is an acquired, often severe, form of dysautonomia.

19 tically and pathophysiologically in acquired dysautonomia.

20 ic dysfunction and more frequent cholinergic dysautonomia.

21 ic function, both can be considered forms of dysautonomia.

22 nguishes these disorders from other types of dysautonomia.

23 from 157 patients with a variety of types of dysautonomia.

24 , we assess CG-2 as a candidate for familial dysautonomia.

25 of 6-[18F]fluorodopamine in 26 patients with dysautonomia.

26 questionnaires are frequently used to assess dysautonomia.

27 pathetic neurons leading to diabetes-induced dysautonomias.

28 ent clinical manifestation (64%) followed by dysautonomia (16 patients [8%]) and encephalopathy (15 p

29 ventilatory insufficiency 40.3%, PDB 28.2%, dysautonomia 21.4% and FTD 14.3%.

30 ned with afferent sensory deficits (55%) and dysautonomia (28%).

31 signs (85%), motor neuron involvement (55%), dysautonomia (50%), and parkinsonism (10%).

32 , 12; cognitive difficulties, 11; ataxia, 8; dysautonomia, 7.

33 ated to increased autonomic symptoms, making dysautonomia a plausible therapeutic target.

34 it of human Elongator (Elp1) causes familial dysautonomia, a severe recessive neuropathy.

35 y effectors of autonomic neuroplasticity and dysautonomia after SCI in mice.

36 ntial for neuromodulation to block or reduce dysautonomia after severe high-level SCI.SIGNIFICANCE ST

37 Migraine, post-concussional syndrome, and dysautonomias also cause persistent dizziness and may be

38 and highlight their contribution to cardiac dysautonomia and deterioration of cardiac function durin

39 Sensory symptoms, oscillopsia, dysautonomia and dysarthria were also variably associate

40 In MSA, severe dysautonomia and early development of combined autonomic

41 otype resembles that of the adults, although dysautonomia and hypoventilation are less frequent or se

42 midodrine supports the hypothesis of partial dysautonomia and indicates that the use of alpha1-agonis

43 vere group, AAPI patients had increased POTS/dysautonomia and respiratory symptoms, and NHB patients

44 The resulting TBI-induced dysautonomia and systemic inflammation contribute to the

45 its strong link with chronic pain, fatigue, dysautonomia and the adverse impact on quality of life.

46 ologic system (neurocognitive impairment and dysautonomia), and shortness of breath.

47 spectrum disorders, schizophrenia, familial dysautonomia, and Alzheimer's disease.

48 enriched phenotype, including parkinsonism, dysautonomia, and cognitive decline, showed posterior co

49 metry, levodopa-induced motor complications, dysautonomia, and dementia than those without mutations.

50 , reduced accessibility of cardiac reserves, dysautonomia, and hypertrophy.

51 her syndromes such as Klippel-Feil, familial dysautonomia, and Marfan syndrome demonstrate high rates

52 ion of SCI-induced structural plasticity and dysautonomia, and reveal the potential for neuromodulati

53 hesias, cranial nerve abnormalities, ataxia, dysautonomia, and skeletal muscle injury with normal ori

54 Prevention of pain and dysautonomia are also clinical targets.

55 Dysautonomias are an important subject in clinical neuro

56 y with clinical features similar to familial dysautonomia as well as contractures, we identified a de

57 evolve, along with cognitive impairment and dysautonomia, as the disease progresses, often dominatin

58 clinical pathophysiologic classification of dysautonomias, based on the occurrence of sympathetic ne

59 Methods for detecting dysautonomia can be as simple as performing a history an

60 G-2 (C9ORF5), was isolated from the familial dysautonomia candidate region on 9q31 using a combinatio

61 direct genomic sequencing from the familial dysautonomia candidate region on 9q31.

62 tis or encephalitis, sympathetic storming or dysautonomia, cardiac arrest, coma, delirium, and stroke

63 also known as Riley-Day syndrome or familial dysautonomia, do not have functional muscle spindle affe

64 Currently, treatments directed toward dysautonomia, dysbiosis, and/or systemic inflammation of

65 gene DYS, which is responsible for familial dysautonomia (FD) and has been mapped to a 0.5-cM region

66 hy the Elp1 gene that is mutated in familial dysautonomia (FD) causes peripheral neuropathy.

67 nalyze the mechanism whereby IKBKAP-familial dysautonomia (FD) exon 20 inclusion is specifically prom

68 Recent research on familial dysautonomia (FD) has focused on the development of ther

69 The autosomal recessive disorder familial dysautonomia (FD) has recently been demonstrated to be c

70 Familial dysautonomia (FD) is a currently untreatable, neurodegen

71 Familial dysautonomia (FD) is a debilitating disorder that affect

72 Familial dysautonomia (FD) is a devastating developmental and pro

73 Familial dysautonomia (FD) is a devastating disorder caused by a

74 Familial dysautonomia (FD) is a rare but fatal peripheral neuropa

75 Familial dysautonomia (FD) is a rare genetic neurologic disorder

76 Familial dysautonomia (FD) is a rare neurodegenerative disease ca

77 Familial dysautonomia (FD) is a rare recessive neurodevelopmental

78 Familial dysautonomia (FD) is a rare sensory and autonomic neurop

79 Familial dysautonomia (FD) is a recessive neurodegenerative disea

80 Familial dysautonomia (FD) is a sensory and autonomic neuropathy

81 Familial dysautonomia (FD) is a severe hereditary sensory and aut

82 Familial dysautonomia (FD) is a severe neurodegenerative disorder

83 Familial dysautonomia (FD) is an autosomal recessive neurodegener

84 Familial dysautonomia (FD) is an autosomal recessive neurodegener

85 Familial dysautonomia (FD) is caused by mutations in IKBKAP, and

86 Familial dysautonomia (FD) is characterized by severe and progres

87 Familial dysautonomia (FD) is the best-known and most common memb

88 Familial dysautonomia (FD) is the most prevalent form of heredita

89 ed to generate and purify iNCs from familial dysautonomia (FD) patient fibroblasts.

90 e defects occur in fibroblasts from Familial Dysautonomia (FD) patients bearing an autosomal recessiv

91 neuropathy in the genetic disorder familial dysautonomia (FD), (3) to show parasymN dysfunction duri

92 Familial dysautonomia (FD), a devastating hereditary sensory and

93 Familial dysautonomia (FD), a rare neurodevelopmental and neurode

94 ere generated from individuals with familial dysautonomia (FD), a rare, fatal genetic disorder affect

95 (IKBKAP) gene as the major cause of familial dysautonomia (FD), a recessive sensory and autonomic neu

96 Familial dysautonomia (FD), also known as HSAN type III, is an au

97 to the high morbidity/mortality of familial dysautonomia (FD), the mechanisms remain unclear.

98 n Elp1p (IKAP) are a known cause of familial dysautonomia (FD).

99 erature and sweating dysfunction in familial dysautonomia (FD).

100 Familial dysautonomia (FD; also known as "Riley-Day syndrome"), a

101 d autonomic neuropathy type III, or familial dysautonomia [FD; Online Mendelian Inheritance in Man (O

102 cluding gastric reflux, joint hypermobility, dysautonomia, flushing and pruritus, and hymenoptera all

103 s including cutaneous flushing and pruritus, dysautonomia, functional gastrointestinal symptoms, chro

104 Dysautonomia has also been recognised in other movement

105 The classification of dysautonomias has been confusing, and the pathophysiolog

106 sing fibroblasts from patients with familial dysautonomia (hereditary sensory and autonomic neuropath

107 65.5%, amnesia 55.6%, hallucinations 51.9%), dysautonomia (hyperhidrosis 86.2%, cardiovascular 48.3%)

108 Dysautonomia in degenerative disorders also affect respi

109 ions are similar across both conditions, but dysautonomia in GBS requires specific attention.

110 are common manifestations of cardiovascular dysautonomia in Parkinson's disease and related synuclei

111 lain sympathetic neuron loss and physiologic dysautonomia in patients with FD.

112 Although the clinical presentation of dysautonomia in these two disorders may overlap, yet pat

113 Dysautonomia increased with duration while cognitive imp

114 this apparently disease specific peripheral dysautonomia is unknown and would be the subject of much

115 sis, patent ductus arteriosus with ligation, dysautonomia, low blood pressure, hypotonic bladder requ

116 Dysautonomia may occur during hemiplegia or in isolation

117 mic questionnaires correlates with objective dysautonomia measured by quantitative autonomic testing.

118 at it may have a role in some forms of human dysautonomia, most of which have no known cause.

119 frequent focal seizures, prominent amnesia, dysautonomia, neuromyotonia and neuropathic pain.

120 It is unknown whether subjective dysautonomia obtained from autonomic questionnaires corr

121 Patients with dysautonomia often have unpredictable and paradoxical ph

122 sfunctional brainstem/vagus nerve signaling, dysautonomia or autonomic dysfunction, ongoing activity

123 Some patients also have or develop dysautonomia or motor involvement depending on whether l

124 thophysiologies include hypovolemia, partial dysautonomia, or a primary hyperadrenergic state.

125 bnormal sympathetic reflexes that exacerbate dysautonomia over time.

126 well defined although exercise intolerance, dysautonomia, pain, as well as neurocognitive and psychi

127 s had accompanying dream enactment behavior, dysautonomia, parkinsonism, sleep transition-related hal

128 sleep behaviour disorder, pain, anxiety and dysautonomia (particularly orthostatic hypotension and u

129 ificantly more abundant in cells of familial dysautonomia patients with IKBKAP (I-kappa-B kinase comp

130 on were detected for either gene in familial dysautonomia patients.

131 tural and functional indices of pathological dysautonomia, providing further evidence that microglia

132 The term dysautonomia refers to a change in autonomic nervous sys

133 tion of ASIC2 recapitulates the pathological dysautonomia seen in heart failure and hypertension and

134 Here, we describe a novel syndrome of pain, dysautonomia, small hands and small feet in a kindred ca

135 out detectable cardiac pathology, as well as dysautonomia, some specific features, and the principles

136 inical manifestation of primary degenerative dysautonomias such as multiple system atrophy (MSA) and

137 es like spinal muscular atrophy and familial dysautonomia that allowed partial modeling of the diseas

138 heart in patients with acquired, idiopathic dysautonomias using thoracic positron-emission tomograph

139 Because those with SCD have dysautonomia, we anticipated that thermal exposure would

140 m supraspinal control, causing systems-wide "dysautonomia." We recently showed that remarkable struct

141 Patients with dysautonomia who did not have sympathetic neurocirculato

142 igrostriatal system of the brain, but also a dysautonomia, with norepinephrine loss in the sympatheti

143 vascular disease associated with sympathetic dysautonomia would have significant therapeutic utility.